アレムツズマブ(遺伝子組換え)

アレムツズマブ(遺伝子組換え) 化学構造式
216503-57-0
CAS番号.
216503-57-0
化学名:
アレムツズマブ(遺伝子組換え)
别名:
アレムツズマブ(遺伝子組換え);アレムツズマブ
英語名:
Alemtuzumab
英語别名:
D02802;MabCampath;Alemtuzumab;Campath (tn);Alemtuzumab (usan/inn);Research Grade Alemtuzumab;Research Grade Alemtuzumab(DHD95101)
CBNumber:
CB91216036
化学式:
分子量:
0
MOL File:
Mol file

アレムツズマブ(遺伝子組換え) 物理性質

外見 :
Liquid
色:
Colorless to light yellow

安全性情報

有毒物質データの 216503-57-0(Hazardous Substances Data)

アレムツズマブ(遺伝子組換え) 価格

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入

アレムツズマブ(遺伝子組換え) 化学特性,用途語,生産方法

説明

Alemtuzumab was first introduced in the US for the treatment of B-cell chronic lymphocytic leukemia (CLL) in patients who have been treated with alkylating agents and have failed fludarabine therapy. Alemtuzumab is a humanized monoclonal antibody of the IgG1 isotype specific for the glycoprotein CD52 expressed on the cell surface of over 95% of normal and malignant B and T lymphocytes and monocytes. It was genetically engineered by adding six hypervariable regions from the heavy-chain and light-chain variable domains of an IgG2a rat monoclonal antibody onto a human IgG1 immunoglobulin molecule. The exact mechanism of action of alemtuzumab is unknown but the antibody probably causes the lysis of lymphocytes via complement fixation and antibody-dependent cytotoxicity. In a phase III clinical trial with 93 fiudarabine-resistant CLL patients, treatment with alemtuzumab gave a positive response in 31 patients with 2 complete remissions and 29 partial remissions. This study demonstrated a higher response rate in patients having malignancy confined to the blood and bone marrow. Alemtuzumab does not seem to penetrate well into solid tissues and it was found to be concentrated in the blood which seems to correlate with the fact that it appears to be inefficient against tumor cells from lymph nodes and extranodal masses. The half-life of the antibody ranged between 23 and 30 hours. Premedication with acetaminophen and diphenhydramine is effective in reducing infusion-related reactions such as fevers, rigors, rash, nausea or hypotension. The most significant adverse effect is lymphopenia resulting in increased risk of opportunistic infections. As a consequence, prophylactic treatment with antibiotics is recommended for patients under alemtuzumab therapy.

使用

Antineoplastic (monoclonal antibody).

一般的な説明

Alemtuzumab (Campath) is humanized MAb (Campath-1H)that is directed against the 21- to 28-kDa cell surface glycoproteinCD52. CD52 is expressed on the surface of normaland malignant B and T lymphocytes, NK cells, monocytes,macrophages, and tissues of the male reproductive system.The Campath-1H antibody is an IgG1 κ form with humanizedvariable and constant regions and CDRs from a ratMAb, Campath-1G.
Alemtuzumab is indicated for the treatment of B-cellchronic lymphocytic leukemia in patients who have beentreated with alkylating agents and who have failed on thistherapy. Alemtuzumab binds to CD52, a nonmodulating antigen that is present on the surface of essentially all B andT lymphocytes; most monocytes, macrophages, and NKcells, and a subpopulation of granulocytes. The proposedmechanism of action is antibody-dependent lysis ofleukemic cells following cell surface binding.

アレムツズマブ(遺伝子組換え) 上流と下流の製品情報

原材料

準備製品


アレムツズマブ(遺伝子組換え) 生産企業

Global( 50)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Shaanxi Haibo Biotechnology Co., Ltd
+undefined18602966907
qinhe02@xaltbio.com China 1000 58
Baoji Guokang Healthchem co.,ltd
+8615604608665 15604608665
dominicguo@gk-bio.com CHINA 9427 58
Hefei Hirisun Pharmatech Co., Ltd
+8615056975894
shawn@hirisunpharm.com CHINA 9923 58
TargetMol Chemicals Inc.
+1-781-999-5354
support@targetmol.com United States 19973 58
LEAPCHEM CO., LTD.
+86-852-30606658
market18@leapchem.com China 43348 58
LGM Pharma 1-(800)-881-8210
inquiries@lgmpharma.com United States 2127 70
Wuhan Fortuna Chemical Co., Ltd 027-59207852 13308628970
buy@fortunachem.com China 2878 58
Dalian Meilun Biotech Co., Ltd. 0411-62910999 13889544652
meilunui@163.com China 4672 58
Nanjing Sunlida Biological Technology Co., Ltd. 025-57798810
sales@sunlidabio.com China 3239 55
Taizhou KEDE Chemical Co., Ltd 0576-84613060 13093829633
sales@kedechemical.com China 298 60

216503-57-0(アレムツズマブ(遺伝子組換え))キーワード:


  • 216503-57-0
  • Alemtuzumab
  • Alemtuzumab (usan/inn)
  • Campath (tn)
  • D02802
  • MabCampath
  • Research Grade Alemtuzumab(DHD95101)
  • Research Grade Alemtuzumab
  • アレムツズマブ(遺伝子組換え)
  • アレムツズマブ
Copyright 2017 © ChemicalBook. All rights reserved